Ipsen and Inspiration Biopharmaceuticals, Inc. announced that they have entered into a partnership to combine their expertise and technologies to develop new recombinant factor products. The two therapies that are farthest along in development are:
- OBI-1, Ipsen’s recombinant porcine (pig) factor VIII product for the treatment of patients with acquired hemophilia and hemophilia A who have developed an inhibitor to factor VIII.
- IB1001, Inspiration’s recombinant factor IX product for the acute and preventive treatment of bleeding in patients with hemophilia B.
Phase III clinical trials for both of these therapies are expected to begin later this year.
Source: Ipsen press release dated January 21, 2010
